Related Experiment Video
Updated: Feb 4, 2026
06:20
Imaging Leukocyte Adhesion to the Vascular Endothelium at High Intraluminal Pressure
Published on: August 23, 2011
16.5K
Cardiotoxicity: Myocardium or Endothelium.
Raúl A Montañez-Valverde1, David Hurtado-de-Mendoza2, Arturo Loaiza-Bonilla3
1Cardiovascular Division, Beth Israel Deaconess Medical Center/Harvard School of Medicine, Boston, USA.
Cureus
|September 25, 2018
Summary
Antineoplastic drugs can cause cardiotoxicity and vascular damage. Research is identifying endothelial biomarkers for early detection and risk stratification of these cardiovascular adverse effects.
Area of Science:
- Cardiology
- Oncology
- Vascular Biology
Background:
- Antineoplastic drugs, particularly anthracyclines, are increasingly linked to cardiotoxicity and vascular damage.
- Endothelial biomarkers are crucial for stratifying cardiovascular risk and diagnosing drug-induced cardiotoxicity.
- Understanding these adverse effects is vital for patient management post-chemotherapy.
Discussion:
- Cardiovascular adverse effects of oncologic drugs extend beyond heart failure to include hypertension and thrombosis.
- Research into endothelial biomarkers can refine cardiotoxicity risk scores.
- Identifying specific biomarkers aids in predicting and mitigating vascular complications.
Key Insights:
- Endothelial biomarkers show promise for early cardiotoxicity detection in cancer patients.
- Vascular damage, including thrombosis and hypertension, is a significant concern with antineoplastic therapies.
- Integrating biomarker data may improve patient outcomes and personalized risk assessment.
Outlook:
- Further research is needed to validate endothelial biomarkers for clinical use.
- Development of targeted therapies to prevent drug-induced vascular damage is essential.
- Enhanced monitoring strategies incorporating biomarkers can improve long-term cardiovascular health in cancer survivors.
